Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma

Publish date:: December 15, 2020

Key clinical point: A dual-targeted CAR T cell therapy may extend responses and prevent relapse.

Major finding: The overall response rate was 93.8%.

Study details: Early phase 1 study of GC012F in 16 patients with relapsed/refractory multiple myeloma.

Disclosures: The study was supported by participating medical centers and Gracell Biotechnologies. Dr. Fu and Dr. Wong reported no relevant conflicts of interest to disclose.

Citation:

Jiang H et al. ASH 2020, Abstract 178.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,